Unknown

Dataset Information

0

Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.


ABSTRACT:

Purpose

This study aimed to investigate the prescribing patterns of medications for chronic diseases in patients with terminal cancer in South Korea as their life expectancy declined.

Methods

This study analyzed data on cancer patients from the National Health Insurance Service (NHIS) database in South Korea. It included a total of 89,606 patients who died of cancer in 2021. We evaluated prescriptions for dyslipidemia, hypertension, diabetes, and osteoporosis at 52, 12, 4, and 1 week prior to death.

Results

A significant proportion of patients nearing death continued to receive prescriptions for chronic disease medications, despite guidelines suggesting that these medications can be discontinued when life expectancy is limited. For instance, 2.6% of patients were prescribed medications for dyslipidemia just 1 week before death, highlighting a discrepancy between clinical practice and recommended guidelines.

Conclusion

These findings underscore the need to reevaluate prescription practices for terminal cancer patients. Optimizing medication use can decrease polypharmacy, reduce adverse drug reactions, and increase the quality of life (QOL) for these individuals.

SUBMITTER: Kim M 

PROVIDER: S-EPMC11891024 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.

Kim Mina M   Kim Yonghwan Y   Park Jae-Min JM  

Journal of hospice and palliative care 20250301 1


<h4>Purpose</h4>This study aimed to investigate the prescribing patterns of medications for chronic diseases in patients with terminal cancer in South Korea as their life expectancy declined.<h4>Methods</h4>This study analyzed data on cancer patients from the National Health Insurance Service (NHIS) database in South Korea. It included a total of 89,606 patients who died of cancer in 2021. We evaluated prescriptions for dyslipidemia, hypertension, diabetes, and osteoporosis at 52, 12, 4, and 1 w  ...[more]

Similar Datasets

| S-EPMC8380597 | biostudies-literature
| S-EPMC10690664 | biostudies-literature
| S-EPMC7577826 | biostudies-literature
| S-EPMC12374942 | biostudies-literature
| S-EPMC7346988 | biostudies-literature